Page last updated: 2024-08-24

mk 458 and Parkinson Disease

mk 458 has been researched along with Parkinson Disease in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Block, GA; Cutler, NR; Sramek, JJ1
Cutler, NR; Hand, EL; McLean, LF; Porras, AG; Reines, SA; Sramek, JJ1
Diederich, NJ; Goetz, CG1
Ahlskog, JE; Bailey, PA; Muenter, MD; Stevens, PM1
Ahlskog, JE; Ahrens, S; Block, GA; Cedarbaum, JM; Cyhan, G; Goetz, CG; Koller, WC; LeWitt, PA; Liss, C; McLean, L1

Reviews

1 review(s) available for mk 458 and Parkinson Disease

ArticleYear
Dopaminergic agonists in the treatment of Parkinson's disease.
    Neurologic clinics, 1992, Volume: 10, Issue:2

    Topics: Apomorphine; Bromocriptine; Dopamine Agents; Humans; Lactose; Lisuride; Methylcellulose; Oxazines; Parkinson Disease; Pergolide; Receptors, Dopamine

1992

Trials

1 trial(s) available for mk 458 and Parkinson Disease

ArticleYear
Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study.
    Clinical neuropharmacology, 1991, Volume: 14, Issue:4

    Topics: Aged; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Lactose; Male; Methylcellulose; Middle Aged; Oxazines; Parkinson Disease

1991

Other Studies

3 other study(ies) available for mk 458 and Parkinson Disease

ArticleYear
Poor tolerability of MK-458.
    Archives of neurology, 1993, Volume: 50, Issue:9

    Topics: Humans; Lactose; Methylcellulose; Oxazines; Parkinson Disease

1993
Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism.
    Clinical pharmacokinetics, 1992, Volume: 22, Issue:3

    Topics: Administration, Oral; Aged; Antiparkinson Agents; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Female; Humans; Lactose; Male; Methylcellulose; Middle Aged; Oxazines; Parkinson Disease; Tablets

1992
Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide)
    Archives of neurology, 1992, Volume: 49, Issue:5

    Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Lactose; Levodopa; Male; Methylcellulose; Middle Aged; Oxazines; Parkinson Disease; Pergolide

1992